GEGeorg Ertl

Georg Ertl

*This is an algorithmically generated author record based on publicly available information.

Georg Ertl has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Die Fabry-Kardiomyopathie als Differenzialdiagnose des akuten Koronarsyndroms

    by Daniel Oder, Stefan Störk, Christoph Wanner, Georg Ertl, Frank Weidemann, Peter Nordbeck

    The progressive cardiomyopathy in patients with Fabry disease is often accompanied by angina pectoris and elevated levels of high-sensitive troponin T (hs-TnT), potentially mimicking acute coronary syndrome. Here, we present to representative cases with focus on clinical, diagnostic and therapeutic settings. An overview on the cardiomyopathy associated with Fabry disease and its role as differential diagnosis of acute coronary syndrome is provided. Fabry cardiomyopathy might exhibit similar clinical and biochemical constellations as seen in acute coronary syndrome. Thus, Fabry cardiomyopathy should be considered a differential diagnosis in acute coronary syndrome, particularly in patients demonstrating left ventricular hypertrophy of unknown origin. Erhöhte Troponin-Werte im Serum sind häufig Ausdruck eines akuten Koronarsyndroms. Allerdings kommen differenzialdiagnostisch auch zahlreiche weitere Pathologien in Betracht. Dazu gehören angeborene und erworbene Kardiomyopathien, die spätestens nach Ausschluss eines akuten Koronarsyndroms weiter abgeklärt bzw. ausgeschlossen werden sollten. Die erhöhten Werte können auch auf eine kardiale Beteiligung bei Morbus Fabry hinweisen. Aufgrund der Seltenheit der Erkrankung wird diese oftmals zunächst nicht erkannt, sodass eine spezifische kausale Therapie ausbleibt oder erst im Spätstadium der Erkrankung initiiert wird.

  • Open Access

    The Year in Cardiology 2013: heart failure

    by Georg Ertl, Frank Ruschitzka

    Heart failure has become a worldwide epidemic of the 21st century with increasing impact on healthcare systems. The 2012 ESC and 2013 ACCF/AHA guidelines have set the stage for current therapy to reduce mortality and morbidity. There is a dawn of hope for therapy of acute and diastolic heart failure; it has become clearer that patients benefit from mitral reconstruction and which patients benefit from heart failure management programmes; genetics and proteomics advance in great strides; competing concepts of cell therapy seem to spiral, hopefully upwards; and we can further nurture our hope for evidence-based individualized diagnostic and therapy.


  • Open Access

    Editorial

    by Georg Ertl

  • Magnetresonanztomografie bei Patienten mit Herzschrittmachern und Defibrillatoren: aktueller Stand

    by Peter Nordbeck, Oliver Ritter, Harald Quick, Mark E. Ladd, Georg Ertl, Wolfgang R. Bauer

    Magnetic resonance imaging is generally regarded a contraindication in patients with implanted cardiac pacemakers or cardioverter defibrillators (ICD) due to the risk of severe complications caused by interactions of the magnetic resonance surrounding and the electric devices. However, recent technical advances in conjunction with a better understanding of the underlying mechanisms responsible for such potentially life-threatening complications have allowed an increasing number of pacemaker and ICD patients to undergo MRI unharmed over the last years. With the availability of even further advanced, „MR-conditional“ devices, which have entered the market, more pacemaker patients will be allowed to undergo MRI safely in the future. Specific precautions and specifications of these devices should be carefully followed as good as possible, to avoid patient risks that might appear with further increasing indications and patient numbers.

  • Medikamentöse Herzinsuffizienztherapie

    by Ulrich Hofmann, Georg Ertl

  • Medicine in Free Market Economies

    by Georg Ertl


  • Failure to Unmask Pseudonormal Diastolic Function by a Valsalva Maneuver

    by Kai Hu, Dan Liu, Markus Niemann, Liv Hatle, Sebastian Herrmann, Wolfram Voelker, Georg Ertl, Bart Bijnens, Frank Weidemann

    Background— For the clinical assessment of patients with dyspnea, the inversion of the early (E) and late (A) transmitral flow during Valsalva maneuver (VM) frequently helps to distinguish pseudonormal from normal filling pattern. However, in an important number of patients, VM fails to reveal the change from dominant early mitral flow velocity toward larger late velocity. Methods and Results— From December 2009 to October 2010, we selected consecutive patients with abnormal filling with (n=25) and without E/A inversion (n=25) during VM. Transmitral, tricuspid, and pulmonary Doppler traces were recorded and the degree of insufficiency was estimated. After evaluating all standard echocardiographic morphological, functional, and flow-related parameters, it became evident that the failure to unmask the pseudonormal filling pattern by VM was related to the degree of the tricuspid insufficiency (TI). TI was graded as mild in 24 of 25 patients in the group with E/A inversion during VM, whereas TI was graded as moderate to severe in 24 of the 25 patients with pseudonormal diastolic function without E/A inversion during VM. Conclusions— Our data suggest that TI is a major factor to prevent E/A inversion during a VM in patients with pseudonormal diastolic function. This probably is due to a decrease in TI resulting in an increase in forward flow rather than the expected decrease during the VM. Thus, whenever a pseudonormal diastolic filling pattern is suspected, the use of a VM is not an informative discriminator in the presence of moderate or severe TI.


  • Toll-like receptors as potential therapeutic targets in cardiac dysfunction

    by Ulrich Hofmann, Georg Ertl, Stefan Frantz

    The innate immune system can detect the highly conserved, relatively invariant structural motifs of pathogens. The most important innate immune receptors, Toll-like receptors (TLRs), represent a first line of defense against infectious pathogens, and play a pivotal role in initiating and shaping innate and adaptive immune responses. TLRs are not only expressed in immune cells, but also in cardiovascular cells. In addition to their role in response to microbial infections, evidence suggests that TLRs can also recognize endogenous ligands and may play a role in mediating cardiomyocyte cell death and survival after non-infectious injury. TLRs could be a link between cardiovascular diseases and the immune system. Experimentally, there is good evidence that TLR activation contributes to development and progression of both acute cardiac injury and chronic heart failure. The role of TLRs in myocardial ischemia-reperfusion, remodeling, septic cardiomyoparthy, autoimmune- and viral myocarditis, anthracycline-induced cardiomyopathy and cardiac hypertrophy, in basic as well as clinical science are discussed. Evidence, mainly from animal experiments, indicates that TLRs contribute to all of the myocardial disease states reviewed in this paper. However, the relevance of TLRs as therapeutic targets remains to be defined as clinical data is sparse.


  • Open Access

    Post-infarct remodelling: contribution of wound healing and inflammation

    by Stefan Frantz, Johann Bauersachs, Georg Ertl

    In human and experimental myocardial infarction (MI), cessation of blood supply leads to rapid necrosis of cardiac myocytes in the ischaemic heart. Immediately after injury, various intra- and intercellular pathways contribute to healing the myocardial wound in order to achieve tissue integrity and function. MI and the consequent loss of myocardium are the major aetiology for heart failure. Despite aggressive primary therapy, prognosis remains poor in patients with large infarction and severe left ventricular dysfunction. Thus, it would be highly desirable to improve healing of the cardiac wound to maintain structure and function of the heart. Healing in the heart occurs in overlapping phases. Herein, we review the inflammatory phase as a trigger of tissue formation.